Celrixafor Injection 1's
₹45766.3*
MRP ₹55812.5
18% off
₹47440.5*
MRP ₹55812.5
15% CB
₹8372 cashback(15%)
Free Delivery
With Circle membership
(Inclusive of all Taxes)
This offer price is valid on orders above ₹800. Apply coupon PHARMA10/PHARMA18 (excluding restricted items)
Provide Delivery Location
Celrixafor Injection 1's belongs to the class of hemopoietic stem cell mobilizer. It is used in the treatment of Non-Hodgkin’s Disease (a blood cancer that affects your lymph system) and multiple myeloma (a type of cancer that affects the plasma cells of the bone marrow) in combination with granulocyte-colony stimulating factor (G-CSF).
Celrixafor Injection 1's contains Plerixafor, which belongs to the hemopoietic stem cell mobilizer class or drugs. It works by binding to the chemokine receptor CXCR4 and inhibits the binding of its cognate ligand CXCL12.
Celrixafor Injection 1's may cause certain side effects, such as nausea, vomiting, headache, dizziness, diarrhoea, flatulence, fatigue, and pain at the site of injection. These side effects do not require medical attention and gradually resolve over time. A trained healthcare professional will administer it. Do not self-administer.
Avoid taking it and inform your doctor if you are allergic to Celrixafor Injection 1's or its components. Before administration, inform your doctor if you have liver/kidney disease, cardiac disorders, blood disorders or respiratory conditions. This medicine is known to cause fetal harm in pregnant women. Hence, inform your doctor if you are pregnant or are planning to become pregnant. Breastfeeding should be discontinued during the treatment.
Celrixafor Injection 1's contains Plerixafor, which belongs to the hemopoietic stem cell mobilizer class or drugs. It works by binding to the chemokine receptor CXCR4 and inhibiting its cognate ligand CXCL12 binding. This mobilizes hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in cancer patients.
Celrixafor Injection 1's should be avoided if you are allergic to it or any other components present in it. Let your doctor know about your complete medical history, including current medication, to rule out any side effects/interactions. Before administration, inform your doctor if you have liver/kidney disease, cardiac disorders, blood disorders, anaemia, or respiratory conditions. Celrixafor Injection 1's may cause the potential for tumor cell mobilization in leukemia patients, haematological effects, and splenic rupture in some patients. Hence, careful monitoring should be done during the entire treatment. This medicine is known to cause fetal harm in pregnant women. Hence, inform your doctor if you are pregnant or are planning to become pregnant. Breastfeeding should be discontinued in nursing mothers during the treatment. Celrixafor Injection 1's should be avoided in children as safety is not established.
Drug-Drug Interactions: No interactions found.
Drug-Food Interactions: No interactions found.
Drug-Disease Interactions: Inform your doctor if you have kidney or liver disease, blood disorders, and pulmonary disorders before receiving Celrixafor Injection 1's.
Non-Hodgkin’s lymphoma: Non-Hodgkin’s disease is a blood cancer that affects your lymph system. It causes the uncontrollable growth of cancer cells in the lymph nodes. The lymph system is a part of the immune system which protects your body from disease and infections. Symptoms include lymph node swelling, abdominal pain, chest pain, cough, fever, and night sweats.
Multiple myeloma: It is a type of cancerous tumour that affects the plasma cells of the bone marrow. These cells collect in the bone marrow and divide uncontrollably, leading to kidney and bone damage. Symptoms include bone pain, loss of appetite, fever, and frequent infections. Generally, multiple myeloma cannot be cured, but the signs and symptoms can be reduced greatly or disappear after a period of time.
Country of origin
Alcohol
Unsafe
It is unknown whether Celrixafor Injection 1's interacts with alcohol or not. Please consult your doctor.
Pregnancy
Unsafe
Celrixafor Injection 1's is not recommended for use in pregnancy as it may harm your fetus. Hence, if you are pregnant or planning pregnancy, inform your doctor before receiving Celrixafor Injection 1's. Effective birth control is necessary during treatment and for one week after your last dose.
Breast Feeding
Unsafe
Celrixafor Injection 1's is not recommended if you are breastfeeding. You should not breastfeed while taking this medication and for one week after your last dose.
Driving
Not applicable
Celrixafor Injection 1's is generally administered to hospitalized patients. Driving is not advised after taking this medicine.
Liver
Caution
If you have a pre-existing or a history of liver disease, inform your doctor before receiving Celrixafor Injection 1's. A dose adjustment may be made, or a suitable alternative may be advised based on your condition.
Kidney
Caution
If you have a pre-existing or a history of kidney disease, inform your doctor before receiving Celrixafor Injection 1's. A dose adjustment may be made, or a suitable alternative may be advised based on your condition.
Children
Unsafe
Celrixafor Injection 1's is not recommended for use in children as the safety and efficacy are not established.
Product Substitutes
We provide you with authentic, trustworthy and relevant information